{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:54:07Z","timestamp":1791237247403,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ijantimicag.2017.03.025","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T07:46:11Z","timestamp":1499499971000},"page":"393-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment"],"prefix":"10.1016","volume":"50","author":[{"given":"Naoki","family":"Murao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ohge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Watadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Uegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Shigemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raita","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Kajihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taijiro","family":"Sueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0010","author":"Wyeth Pharmaceuticals Inc"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0015","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1128\/AAC.36.12.2766","article-title":"Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections","volume":"36","author":"Brismar","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0020","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00019053-200119110-00006","article-title":"Piperacillin\/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections","volume":"19","author":"Young","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0025","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1128\/AAC.00509-08","article-title":"Piperacillin-tazobactam penetration into human pancreatic juice","volume":"52","author":"Bertazzoni Minelli","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"S\u20132","key":"10.1016\/j.ijantimicag.2017.03.025_bib0030","first-page":"568","article-title":"Penetration of tazobactam\/piperacillin into intraperitoneal exudate after gastrectomy","volume":"42","author":"Shimizu","year":"1994","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0035","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","article-title":"Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics","volume":"21","author":"Kobayashi","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A pharmacokinetic analysis program (multi) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J Pharmacobiodyn"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijantimicag.2013.08.016","article-title":"Application of pharmacokinetic\/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches","volume":"43","author":"Barbour","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijantimicag.2007.04.012","article-title":"Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients","volume":"30","author":"Ikawa","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2007.06.001","article-title":"Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients","volume":"30","author":"Ikawa","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archsurg.1983.01390020055010","article-title":"Penetration of eight \u03b2-lactam antibiotics into the peritoneal fluid","volume":"118","author":"Wittman","year":"1983","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1472-8206.1991.tb00768.x","article-title":"Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis","volume":"5","author":"Hary","year":"1991","journal-title":"Fundam Clin Pharmacol"},{"issue":"S\u20132","key":"10.1016\/j.ijantimicag.2017.03.025_bib0070","first-page":"559","article-title":"Basic and clinical studies of tazobactam\/piperacillin in urinary tract infection","volume":"42","author":"Kitagawa","year":"1994","journal-title":"Jpn J Chemother"},{"issue":"S\u20132","key":"10.1016\/j.ijantimicag.2017.03.025_bib0075","first-page":"332","article-title":"In vitro antimicrobial activity, penetration rate into lung tissue, and therapeutic efficacy of tazobactam\/piperacillin in the treatment of respiratory tract infections","volume":"42","author":"Watanabe","year":"1994","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0080","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jcms.2008.06.003","article-title":"Concentrations of piperacillin-tazobactam in human jaw and hip bone","volume":"36","author":"AL-Nawas","year":"2008","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0090","article-title":"Performance Standards for Antimicrobial Susceptibility Testing","volume":"32","author":"Clinical and Laboratory Standards Institute","year":"2012","journal-title":"Twenty-Second Inform Suppl"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0095","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0100","first-page":"71","article-title":"Clinical analysis and penetration of the bronchoalveolar area with panipenem\/betamipron (PAPM\/BP) in patients with chronic bronchitis","volume":"17","author":"Mori","year":"1998","journal-title":"Respir Res"},{"key":"10.1016\/j.ijantimicag.2017.03.025_bib0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-5173(97)00103-8","article-title":"The effect of tazobactam on the pharmacokinetics and the antibacterial activity of piperacillin in dogs","volume":"153","author":"Zaghloul","year":"1997","journal-title":"Int J Pharm"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T12:50:07Z","timestamp":1535633407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0924857917302546"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.025","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}